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Background/Purpose: Coronavirus disease 2019 (COVID-19) is associated with
increased risk of acute ischemic stroke (AIS), however, there is a paucity of data
regarding outcomes after administration of intravenous tissue plasminogen activa-
tor (IV tPA) for stroke in patients with COVID-19.
Methods: We present a multicenter case series from 9 centers in the United States of
patients with acute neurological deficits consistent with AIS and COVID-19 who
were treated with IV tPA.
Results: We identified 13 patients (mean age 62 (§9.8) years, 9 (69.2%) male). All
received IV tPA and 3 cases also underwent mechanical thrombectomy. All patients
had systemic symptoms consistent with COVID-19 at the time of admission: fever
(5 patients), cough (7 patients), and dyspnea (8 patients). The median admission
NIH stroke scale (NIHSS) score was 14.5 (range 326) and most patients (61.5%)
improved at follow up (median NIHSS score 7.5, range 025). No systemic or
symptomatic intracranial hemorrhages were seen. Stroke mechanisms included car-
dioembolic (3 patients), large artery atherosclerosis (2 patients), small vessel disease
(1 patient), embolic stroke of undetermined source (3 patients), and cryptogenic
with incomplete investigation (1 patient). Three patients were determined to have
transient ischemic attacks or aborted strokes. Two out of 12 (16.6%) patients had
elevated fibrinogen levels on admission (mean 262.2 § 87.5 mg/dl), and 7 out of 11
(63.6%) patients had an elevated D-dimer level (mean 4284.6 §3368.9 ng/ml).
Conclusions: IV tPA may be safe and efficacious in COVID-19, but larger studies are
needed to validate these results.
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Introduction
Preliminary reports suggest that patients with Coronavi-
rus Disease 2019 (COVID-19) are at high risk of hemato-
logic complications, including disseminated intravascular
coagulation (DIC).13 Patients with COVID-19 may exhibit
hemostatic abnormalities with the potential to precipitate
both hemorrhagic and thromboembolic events, including
mild thrombocytopenia, prolongation of both prothrombin
time and international normalized ratio, and shortened
activated partial thromboplastin time, and both ischemic
stroke and intracerebral hemorrhage have been described
in infected patients.47 However, limited evidence exists in
the literature for management of acute stroke in COVID-19
given the concomitant risk of hemorrhage, and recommen-
dations are based on consensus only.8
The safety and efficacy of intravenous tissue plasmino-
gen activator (IV tPA) for acute ischemic stroke in patients
with COVID-19 remain unknown.1 We present the out-
comes of a multicenter series of patients with confirmed
COVID-19 infection who were treated with IV tPA for
suspected acute ischemic stroke.
Methods
All patients with COVID-19 who received IV tPA for
acute neurological deficits between March 1, 2020 and
July 1, 2020 were identified at the participating hospitals
by the corresponding stroke provider at each institution.
The study protocol was approved or given exemptions by
local institutional review boards. All patients included
were diagnosed with COVID-19 by severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR from
a nasopharyngeal swab, presented with acute neurologi-
cal deficits (< 24 h), received IV tPA per acute ischemic
stroke American Heart Association guidelines, and under-
went brain and intracranial vessel imaging.9 Laboratory
values were obtained within 24 hours of admission
(Table 1). Stroke mechanism was primarily defined using
the TOAST classification, with some strokes classified as
embolic strokes of undetermined source (ESUS). 10,11
Results
Patient characteristics
A total of 13 patients were identified at 9 centers. Mean
age was 62 (§9.8) years, and 9 (69.2%) were male (Table 1).
Median NIH stroke scale (NIHSS) score on admission was
14.5 (range 326). Eleven patients were treated within the
standard window (4.5 h) with mean elapsed time between
last known well and IV tPA administration of 155.4
(§24.2) min. One patient was treated with IV tPA in an
extended window based on MRI/CT perfusion findings
(600 min). One patient had IV tPA administered beyond
the standard window based on clinical decision making
with the patient (280 min).
CT angiography revealed large vessel occlusion (LVO)
in 8 cases (61.5%) and MRI brain confirmed acute ische-
mic stroke in 4 cases (30.7%). Cerebral digital subtraction
angiogram was performed in 4 (30.7%) patients. Three
underwent thrombectomy, achieving thrombolysis in
cerebral infarction (TICI) 3 reperfusion without complica-
tions, while one patient was found to have patent large
vessels after IV tPA administration. The other four
patients with LVO were not considered for thrombectomy
due to unfavorable anatomy with proximal vessel stenosis
or had intact collateral circulation with blood flow recon-
stitution distal to the occlusion site.
Stroke mechanisms included cardioembolic (3 patients),
large artery atherosclerosis (2 patients), small vessel dis-
ease (1 patient), ESUS (3 patients) or cryptogenic with
incomplete investigation (1 patient). Three patients were
determined to have transient ischemic attacks (TIAs) or
aborted strokes.
Systemic symptoms of COVID-19 were present in all
patients, including fever (5 patients), cough (7 patients),
and dyspnea (8 patients). Two out of 12 (16.6%) patients
with fibrinogen levels tested had elevated fibrinogen lev-
els on admission (mean 262.2 § 87.5 mg/dl), and 7 out of
11 (63.6%) patients with D-dimer levels tested had an ele-
vated D-dimer level (mean 4284.6 §3368.9 ng/ml).
Safety and efficacy of IV tPA
No patients had symptomatic systemic or intracranial
hemorrhage. One patient developed asymptomatic pete-
chial hemorrhage in the area of infarction noted on routine
follow-up imaging at 24 h. Median NIHSS score for
patients with stroke at follow-up was 7.5 (range 025), and
8 (61.5%) patients had an improvement in their NIHSS
score of 4 points or more. All patients survived to hospital
discharge however one elderly patient was discharged to
hospice because of severe respiratory symptoms.
Discussion
We describe a series of patients with COVID-19 who pre-
sented from the community and received IV tPA for acute
ischemic stroke. In our series, intravenous thrombolysis
was not associated with symptomatic complications, and
the majority of patients had clinical improvement at fol-
low-up.
Preliminary reports found a 1% incidence of stroke
among hospitalized patients with COVID-19.4,12 More
recently, acute ischemic strokes have been noted in the
early stages of illness, and LVO has been reported as the
presenting symptom of COVID-19.1,13,14 Patients with
COVID-19 can also present with delirium, meningoen-
cephalitis, and fever, which may be considered stroke
mimics, posing a challenge in the evaluation for thrombol-
ysis eligibility. 6,12 In 2 case series of LVO in patients with
COVID-19, 45% of patients had encephalopathy at admis-
sion, suggesting that reduced level of consciousness could
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Table 1. Clinical characteristics of patients with acute neurological deficits and COVID-19
Variable Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Age (years) 73 47 55 72 24 93 74 84 57 75




















Medications None Metformin Olanzapine Valproic
acid












7 8 17 26 18 16 21 13 10 24
NIHSS score at 24h 9 0 4 23 0 25 (intubated) N/A 7 2 22
NIHSS score at last
follow up
8 (day 11) 0 (day 3) 2 (day 12) 16 (day 2) 0 (day 1) N/A (improvement
noted)
0 (day 41) 7 (day 4) 0 (day 12) 19 (day 2)
Outcome status Discharged to
rehabilitation facility
Discharged home Discharged to long
term acute facility
Discharged home Discharged home Discharged to
outpatient hospice.






Time to presentation 60 minutes 60 minutes 100 minutes 113 minutes 120 minutes 150 minutes 45 minutes 540 minutes 60 minutes 102 minutes
LKW to needle 160 minutes 100 minutes 150 minutes 184 minutes 165 minutes 180 minutes 120 minutes 600 minutes 115 minutes 225 minutes









































Imaging CT, CTA, MRI CT, CTA, MRI, DSA CT, CTA, MRI CT, CTA CT, CTA, CTP CT, CTA, DSA CT, CTA, DSA CT, CTA CT Perfusion CT, CTA, MRI CT, CTA, MRI
Imaging Results CTA: unremarkable
MRI: Restricted dif-
fusion in left internal
capsule, left parietal
and right frontal lobes
CTA: Left middle cere-
bral artery occlusion
at M2 segment DSA:









occlusion at distal M1
segment










occlusion at M1 seg-
ment DSA: TICI III
CTA: Unremarkable
MRI: Restricted dif-





fusion in both cere-
bellar hemispheres
CTA: Left middle cere-
bral artery occlusion
at M2 segment L ICA
thrombus MRI:
Restricted diffusion in
in left insula and left
frontal and temporal
lobes





Covid-19 symptoms Fever Cough Dyspnea Cough Fever Encephalopathy Cough Fever Dyspnea Fever Dyspnea Cough Dyspnea
Malaise
Cough Dyspnea Dyspnea Cough
White cell count
(1000/per mm3)




5.2 1.7 2.4 0.7 3.1 0.7 1.4 1.4 1.5 1.21
Platelet count
(1000/per mm3)
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be a common presenting symptom in patients with
COVID-19-associated stroke.1,13 In our series, 61.5%
patients had large vessel occlusion, but only 7% devel-
oped encephalopathy. Of note, although the Wuhan find-
ings suggested that stroke was more common among
critically ill patients, the patients in our series presented
from the community with mild viral illness.4 Preliminary
reports also suggest more severe illness in male patients
with COVID-19, an observation that may be reflected in
the male predominance of our cohort.
Growing evidence suggests SARS-CoV-2 infection is
associated with a pro-thrombotic state. This process is
mediated by an inflammatory cascade that leads to ele-
vated D-dimer and fibrinogen levels, low anti-thrombin
III levels and pulmonary congestion with microvascular
thromboses, especially in critically ill patients.2 A clot
waveform analysis study in patients with COVID-19 dem-
onstrated that hypercoagulability preceded or coincided
with severe illness.15 Anti-phospholipid antibodies have
been detected in some COVID-19 patients with thrombo-
embolic events, including those with LVOs and
strokes.13,16 Our study shows a wide distribution of stroke
etiologies, suggesting that COVID-19 may increase the
risk for stroke through a variety of mechanisms, including
those seen in other viral disorders.17 Further studies are
required to elucidate stroke etiology and any causal rela-
tionship between SARS-CoV-2 infection and stroke.
IV tPA has been used anecdotally in COVID-19 to treat
acute respiratory distress syndrome, but no published
data exist specifically on the safety of IV tPA for acute
ischemic stroke treatment.2 COVID-19 may also increase
the risk of systemic or cerebral hemorrhagic complica-
tions, and has also been reported in association with acute
hemorrhagic necrotizing encephalopathy.18 Our series
suggests that symptomatic hemorrhagic complications
with IV tPA in patients with COVID-19 are infrequent
and lower than the rate of complications in the general
population (between 2% and 3.3%), reiterating a pro-coag-
ulable state rather than a bleeding disorder.19,20 Larger
studies correlating outcomes post-thrombolysis with
hemostatic measures such as d-dimer, fibrinogen levels,
and thromboelastography are needed to better under-
stand which patients are most likely to safely benefit from
IV tPA administration.
Post-mortem studies have found additional evidence of
fibrin-rich thrombi in patients with COVID-19, raising con-
cern that IV tPA may be of limited benefit in this patient
population in the setting of prior studies demonstrating a
lower efficacy of tPA thrombolysis in thrombi with high
fibrin content compared with erythrocyte-rich emboli.21,22
However, the majority of included patients had an NIHSS
score improvement of 4 or more points and were dis-
charged home, suggesting that IV tPA is efficacious in
these patients. Given the small number of patients in our
series, our observations should be taken with caution. The
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Table 1. Continuation
Variable Patient 11 Patient 12 Patient 13
Age (years) 53 58 41
Sex Female Male Male
Medical history and stroke risk factors None None Hypertension Diabetes Heart Failure Morbid Obesity
Medications None None Losartan Metformin Glipizide Furosemide
NIHSS score at admission 3 4 8
NIHSS score at 24h 1 3 21 (intubated)
NIHSS score at last follow up 0 (day 3) 3 (day 2) 19 (intubated day 24)
Outcome status Home Home n/a
Time to presentation 133 minutes 122 minutes 85 minutes
LKW to needle 167 minutes 280 minutes 154 minutes
Complications None None None
Signs and symptoms of stroke Aphasia Right sensory loss Aphasia Left Hemianopia Dysarthria Right hemiparesis
Imaging CT, CTA, CTP, DSA CT, CTA CT, CTA
Imaging Results CTA: Left Middle Cerebral artery occlusion at M1 segment
DSA: TICI III
CTA: Right middle cerebral artery occlusion at M2
segment
CT: Left temporoparietal and occipital hypodensities. Right
parietal hypodensity. CTA: Unremarkable
Treatment for stroke tPA Thrombectomy TICI III tPA tPA
Covid-19 symptoms Fever Dyspnea Cough Dyspnea None
White cell count (1000/per mm3) 7.2 6.8 7.7
Absolute Lymphocyte count (1000/per
mm3)
2.1 1.0 3.5
Platelet count (1000/per mm3) 210 464 223
Prothrombin time (sec) 12.8 13.5 14.2
Activated partial thromboplastin time
(sec)
30 29 25pt
Fibrinogen (mg/dl) 265 132 266
D-dimer (ng/ml) 104 488 16.554
Ferritin (ng/ml) 65 446 740
Transthoracic echocardiogram No LAE No cardiac thrombus No LAE No cardiac thrombus Cardiomyopathy EF 10% No cardiac thrombus
Atrial Fibrillation Not detected Not detected Atrial tachycardias
Stroke mechanism ESUS ESUS Cardioembolic
CT: computerized tomography
CTA: computed tomography angiography
CTP: CT perfusion
CAD: coronary artery disease
CMO: comfort measures only
DSA: Digital subtraction angiography
ESUS: Embolic stroke of undetermined source
LA: Left atrium
LAE: left atrial enlargement.
LKW: Last known well
LVO: Large vessel occlusion
N/A: Not available.
NIHSS: National Institutes of Health stroke scale
RWA: regional wall abnormality
SVD: Small vessel disease
TIA: Transient ischemic attack
TICI: Thrombolysis in cerebral infarction
Reference ranges:
White blood count: 4.500 to 11.000 per cubic millimeter
Absolute lymphocytes: 1.000 to 4.800 per cubic millimeter
Platelet count: 150.000 to 450.000 per cubic millimeter
Prothrombin time: 12.3 to 14.9 seconds
Activated partial-thromboplastin time: 25.4 to 34.9 seconds
Fibrinogen: 175 to 450 mg per deciliter;
D-dimer: 0 to 500 ng per milliliter
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strokes (median NIHSS 14.5) and presented from the com-
munity. Therefore, our results may not be generalizable to
those with mild strokes or who are critically ill.
In spite of the uncertain hematologic effects of COVID-
19, our findings suggest that IV tPA may be used safely in
acute ischemic stroke patients with COVID-19 and is asso-
ciated with improved outcomes. Larger studies are
needed to better understand safety and efficacy in this
patient population.
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